Ian Wilkinson to give webinar to Chinese Antibody Society
On Saturday 10th September our CSO, Ian Wilkinson, will be giving a webinar to the Chinese Antibody Society ...
Read More Patent granted for mAbsolve’s Fc silencing technology
On 5 Jul 2022 the UK Intellectual Property Office granted Patent number GB2595299 to mAbsolve. Publication of the ...
Read More Scancell license STR technology
Scancell, a UK based company developing anti-glycan antibodies, have today announced an agreement with mAbsolve to license our ...
Read More Antibody Analytics Licenses Novel Fc Silencing Technology from mAbsolve
Fully silent antibodies as true negative controls for in vitro and cell-based effector function assays Antibody Analytics Ltd., ...
Read More mAbsolve to present STR technology at PEGS Boston 2022
Our CSO, Ian Wilkinson, will be attending PEGS Boston in the week of 2-6th May. Our antibody silencing ...
Read More mAbsolve to present webinar hosted by The Antibody Society
Our CSO, Ian Wilkinson, will be presenting on the importance of attenuating effector functions in therapeutics antibodies as ...
Read More Absolute Antibody Licenses Novel Fc Silencing Technology from mAbsolve
Absolute Antibody Ltd., an industry-leading provider of recombinant antibody products and services, and mAbsolve, developers of a novel ...
Read More evitria AG announces license of mAbsolve STR technology
evitria AG, the market-leading transient CHO expression service provider, today announces the closing of a license agreement with ...
Read More mAbsolve Quarterly Company Update
This quarter saw our publication on the STR silencing technology accepted and published in PLOS ONE (see here). ...
Read More - « Previous
- 1
- 2
- 3
- 4
- Next »